Skip to content

Fetotoxicity of NSAIDS and RAAS-inhibitors in the 2nd and 3rd trimester of pregnancy (paediatric-nephrologic approach)

Fetotoxicity of NSAIDS and RAAS-inhibitors in the 2nd and 3rd trimester of pregnancy (paediatric-nephrologic approach) - NSAIDs and RAAS-inhibitors in the 2nd and 3rd trimester of pregnancy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00011861
Enrollment
250
Registered
2017-03-31
Start date
2017-01-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I10 Q61.4 Q60

Interventions

Group 1: Children and teenagers with renal dysplasia, renal hypoplasia or essential hypertension are evaluated regarding certain medication (NSAIDs, metamizole, RAAS-inhibitors) during pregnancy (case

Sponsors

Pharmakovigilanzzentrum Embryonaltoxikologie Charité-Universitätsmedizin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 16 Years

Inclusion criteria

Inclusion criteria: Patients who had an apointment in the pediatric clinic for nephrology in the years 2015 and 2016.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Are renal hypoplasia or renal dysplasia or hypertension in children and adolescents more frequent when the mother has taken an NSAID, metamizole or RAAS-inhibitor in the second half of pregnancy? For this purpose, all patients who were seen in the Charité clinic for pediatric nephrology in the past two years will be contacted by questionnaire.

Secondary

MeasureTime frame
Are there any signs of a minimum exposure time and/or a minimum dose? For this purpose, all patients who were seen in the Charité clinic for pediatric nephrology in the past two years will be contacted by questionnaire.

Countries

Germany

Contacts

Public ContactStephanie Padberg

Pharmakovigilanzzentrum Embryonaltoxikologie Charité-Universitätsmedizin

stephanie.padberg@charite.de+49-30-3450525705

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026